Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Graffinity and Elan launch fragment-based drug discovery collaboration

Abstract:
Graffinity Pharmaceuticals GmbH announced today that it has entered into a research collaboration with Elan Pharmaceuticals, Inc., a subsidiary of Elan Corporation, plc (NYSE:ELN). Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of novel small molecule hits against a number of drug targets. Elan will gain access to Graffinity's proprietary fragment-based drug discovery technology which uses chemical microarrays and surface plasmon resonance to screen for small molecule fragments that bind to a variety of drug targets. The identification of novel modes of action and chemistry is a major focus of the collaboration. Financial details of the transaction were not disclosed.

Graffinity and Elan launch fragment-based drug discovery collaboration

HEIDELBERG, Germany | Posted on January 26th, 2009

Mathias Woker, Chief Business Officer of Graffinity, stated, "We are very pleased that Elan has decided to work with us. With this transaction we are launching our third drug discovery collaboration with a major life science company within the past nine months. This collaboration marks our transition to becoming the leading fragment-based drug discovery company."

Kristina Schmidt, CEO of Graffinity, remarked, "The reason for the heightened attention that our fragment screening approach currently receives, lies in three key advantages that only Graffinity offers in combination: First, Graffinity's technology provides the broadest and deepest primary screen for fragment hits ever developed, second, the platform delivers readily usable novel chemistry within only four months, and thirdly, the Graffinity team possesses unparalleled know-how based on having screened more drug targets than any other team in the fragment space."

####

About Graffinity Pharmaceuticals GmbH
Heidelberg, Germany based Graffinity Pharmaceuticals is a leader in the field of small molecule fragment based drug discovery. The company pursues high-profile drug discovery collaborations with leading pharmaceutical and biotechnology companies worldwide. Graffinity employs a flexible business model which allows it to tailor programs to the specific needs of each partner and offers numerous benefits to its customers on a straightforward fee-for-service basis. Graffinity’s fragment screening platform combines chemical microarrays with a proprietary method for the standardized, label-free detection of compound-protein interactions via SPR imaging. The company’s rapid and scalable drug discovery technology explores a rich chemical universe to identify drug fragments which address challenging drug targets. With its 110,000-compound library that contains 23,000 true fragments, Graffinity possesses one of the most diverse fragment libraries. During the past three years Graffinity has established collaborations with pharmaceutical and biotechnology partners including Amgen, AstraZeneca, Boehringer-Ingelheim, Pfizer and Rigel.

Graffinity’s unique fragment based discovery platform has been invented in 1998, and has been in routine industrial use since 2002 in screening more than 80 drug targets.

For more information, please click here

Contacts:
Graffinity Media Contact for Europe:

Dr. Kristina Schmidt
CEO
Graffinity Pharmaceuticals GmbH
Tel. +49 6221 6510-112



Graffinity Media Contact for the Americas and Asia:

Mathias Woker
CBO
Graffinity Pharmaceuticals GmbH
Tel. +1 (401) 301-1086

Copyright © Graffinity Pharmaceuticals GmbH

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

How to maximize the superconducting critical temperature in a molecular superconductor: International team led by Tohoku University opens new route for discovering high Tc superconductors April 19th, 2015

Engineer improves rechargeable batteries with MoS2 nano 'sandwich' April 18th, 2015

Nanocomposites Play Effective Role in Production of Smart Fibers April 18th, 2015

Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015

Nanomedicine

Optical resonance-based biosensors designed for medical applications April 18th, 2015

Nanocomposites Play Effective Role in Production of Smart Fibers April 18th, 2015

Novel nanoparticles could save soldiers' lives after explosions April 15th, 2015

Nanoparticles at specific temperature stimulate antitumor response: Dartmouth researchers identify precise heat to boost immune system against cancer tumors April 14th, 2015

Announcements

How to maximize the superconducting critical temperature in a molecular superconductor: International team led by Tohoku University opens new route for discovering high Tc superconductors April 19th, 2015

Iranian Foodstuff, Agricultural Industries Welcome Nanotechnology Packaging Bags April 18th, 2015

Nanocomposites Play Effective Role in Production of Smart Fibers April 18th, 2015

Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015

Alliances/Partnerships/Distributorships

How can you see an atom? (video) April 10th, 2015

FibeRio and VF Corporation Form Strategic Partnership to Lead the Apparel and Footwear Markets in Nanofiber Technology April 8th, 2015

UK National Graphene Institute Selects Bruker as Official Partner: World-Leading Graphene Research Facility Purchases Multiple Bruker AFMs April 7th, 2015

NXP and GLOBALFOUNDRIES Announce Production of 40nm Embedded Non-Volatile Memory Technology: Co-developed technology to leverage GLOBALFOUNDRIES 40nm process technology platform March 24th, 2015

Research partnerships

Beyond the lithium ion -- a significant step toward a better performing battery April 18th, 2015

Light in a spin: Researchers demonstrate angular accelerating light April 15th, 2015

Graphene pushes the speed limit of light-to-electricity conversion: Researchers from ICFO, MIT and UC Riverside have been able to develop a graphene-based photodetector capable of converting absorbed light into an electrical voltage at ultrafast timescales April 14th, 2015

Scientists create invisible objects without metamaterial cloaking April 14th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE